Cost-Effectiveness of Switching to the Nonavale...

By Rene Pretorius

January 13, 2025

A recent study on the cost-effectiveness of transitioning from the bivalent human papillomavirus vaccine (2vHPV) to the nonavalent vacci...
Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate
AI Tool Predicts Type 2 Diabetes Risk via ECG Up to 10 Years Early
Zepbound Outperforms Wegovy in Weight Loss Trial
Strengthening EU Health Competitiveness: MedTech Europe’s Call for Stra...
Boosting Biopharma SMEs in Europe
Urgent Call for Universal Diabetes Care in Europe Amidst Political Apathy
NICE’s Position on AI in Evidence Generation
Diabetes Crisis in Europe: Urgent Public Health and Economic Challenge
Chancellor Announces £50 Million Boost for UK Medicines Manufacturing
Healthcare for Older Adults in Türkiye: A Call for Reform
CHEERS-AI Economic Evaluation
Olympus and Proximie Forge Partnership to Transform Digital Healthcare